Clinical Cancer Research

Volume 11, Number 4
February 15, 2005

CONTENTS

The Biology Behind

1355 **Nucleotide Excision Repair, Oxidative Damage, DNA Sequence Polymorphisms, and Cancer Treatment.** Stephanie Q. Hutsell and Aziz Sancar
□□ See Gu *et al*., p. 1408

Editorial

1358 **Histologic Evaluation of Bronchial Squamous Lesions: Any Role in Lung Cancer Risk Assessment?** Ignacio I. Wistuba

Perspective

1361 **Thrombopoietic Factors in Chronic Bone Marrow Failure States: The Platelet Problem Revisited.** Razelle Kurzrock

Human Cancer Biology

1368 **Somatic Mutations of Epidermal Growth Factor Receptor in Colorectal Carcinoma.** Hisashi Nagahara, Koshi Mimori, Mitsuhiko Ohta, Tohru Utsunomiya, Hiroshi Inoue, Graham F. Barnard, Masaichi Ohira, Kosei Hirakawa, and Masaki Mori

1372 **Characterization of *CEBPA* Mutations in Acute Myeloid Leukemia: Most Patients with *CEBPA* Mutations Have Biallelic Mutations and Show a Distinct Immunophenotype of the Leukemic Cells.** Liang-In Lin, Chien-Yuan Chen, Dong-Tsamn Lin, Woei Tsay, Jih-Luh Tang, You-Chia Yeh, Hwei-Ling Shen, Fang-Hsien Su, Ming Yao, Sheng-Yi Huang, and Hwei-Fang Tien

1380 **Down-Regulation of *LATS1* and *LATS2* mRNA Expression by Promoter Hypermethylation and Its Association with Biologically Aggressive Phenotype in Human Breast Cancers.** Yuri Takahashi, Yasuo Miyoshi, Chie Takahata, Natsumi Irahara, Tetsuya Taguchi, Yasuhiro Tamaki, and Shinzaburo Noguchi

1386 **Expression of Activated Signal Transducer and Activator of Transcription 3 Predicts Expression of Vascular Endothelial Growth Factor in and Angiogenic Phenotype of Human Gastric Cancer.** Weida Gong, Liwei Wang, James C. Yao, Jaffer A. Ajani, Daoyan Wei, Kenneth D. Aldape, Keping Xie, Raymond Sawaya, and Suyun Huang

Imaging, Diagnosis, Prognosis

1394 **Prospective Study of Quantitation of Plasma DNA Levels in the Diagnosis of Malignant versus Benign Prostate Disease.** Jane L. Boddy, Shira Gal, Peter R. Malone, Adrian L. Harris, and Jim S. Wainscoat

1400 **Alteration of Gene Expression in Macroscopically Normal Colonic Mucosa from Individuals with a Family History of Sporadic Colon Cancer.** Chun-Yi Hao, Dan H. Moore, Patrick Wong, James L. Bennington, Nancy M. Lee, and Ling-Chun Chen

1408 **Nucleotide Excision Repair Gene Polymorphisms and Recurrence after Treatment for Superficial Bladder Cancer.** Jian Gu, Hua Zhao, Colin P. Dinney, Yong Zhu, Dan Leibovici, Carlos E. Bermejo, H. Barton Grossman, and Xifeng Wu

1416 **Risk Assessment in Patients with Acute Myeloid Leukemia and a Normal Karyotype.** Marianne Bienz, Madleina Ludwig, Beatrice U. Mueller, Elisabeth Oppliger Leibundgut, Daniel Ratschiller, Max Solenthaler, Martin F. Fey, and Thomas Pabst

1425 **Pathologic Assessment of Melanoma Sentinel Nodes: A Role for Molecular Analysis Using Quantitative Real-Time Reverse Transcription-PCR for MART-1 and Tyrosinase Messenger RNA.** Helene Nortvig Abrahamsen, Boe Sandahl Sorensen, Ebba Nexo, Stephen J. Hamilton-Dutoit, Jørn Larsen, and Torben Steiniche

1434 **Prognostic Significance of Vascular Endothelial Growth Factor Immunohistochemical Expression in Head and Neck Squamous Cell Carcinoma: A Meta-Analysis.** Panayiotis A. Kyzas, Isabella W. Cunha, and John P.A. Ioannidis

1441 **Serum Mannan-Binding Lectin-Associated Serine Protease 2 Levels in Colorectal Cancer: Relation to Recurrence and Mortality.** Henriette Ytting, Ib Jarle Christensen, Steffen Thiel, Jens Christian Jensenius, and Hans Jørgen Nielsen

1447 **Combined Evaluation of Expressions of Cyclin E and p53 Proteins as Prognostic Factors for Patients with Gastric Cancer.** Kamal E. Bani-Hani, Nidal M. Almasri, Yousef S. Khader, Fawzi M. Sheyab, and Hanan N. Karam

1454 **An ^{19}F Magnetic Resonance–Based *In Vivo* Assay of Solid Tumor Methotrexate Resistance: Proof of Principle.** William M. Spees, Terence P.F. Gade, Guangli Yang, William P. Tong, William G. Bornmann, Richard Gorlick, and Jason A. Koutcher

1462 Prognostic Effect of Epidermal Growth Factor Receptor and EGFRvIII in Glioblastoma Multiforme Patients. Amy B. Heimberger, Roman Hlatky, Dima Suki, David Yang, Jeff Weinberg, Mark Gilbert, Raymond Sawaya, and Kenneth Aldape

1467 Outcome in Hodgkin's Lymphoma Can Be Predicted from the Presence of Accompanying Cytotoxic and Regulatory T Cells. Tomás Álvaro, Marylène Lejeune, Mª Teresa Salvadó, Ramón Bosch, Juan F. García, Joaquín Jaén, Alison H. Banham, Giovanna Roncador, Carlos Montalbán, and Miguel A. Piris

Cancer Therapy: Clinical

1474 A Potent Immunogenic General Cancer Vaccine That Targets Survivin, an Inhibitor of Apoptosis Proteins. Satomi Idenoue, Yoshihiko Hirohashi, Toshihiko Torigoe, Yuriko Sato, Yasuaki Tamura, Hiroyuki Hariu, Masaaki Yamamoto, Takehiro Kurotaki, Tetsuhiro Tsuruma, Hiroko Asanuma, Takayuki Kanaseki, Hideyuki Ikeda, Kiyoteru Kashiwagi, Minoru Okazaki, Kazuaki Sasaki, Takashi Sato, Tousei Ohmura, Fumitake Hata, Koji Yamaguchi, Koichi Hirata, and Noriyuki Sato

1483 *In vivo* Radioiodide Imaging and Treatment of Breast Cancer Xenografts after MUC1-Driven Expression of the Sodium Iodide Symporter. Roisin M. Dwyer, Elizabeth R. Bergert, Michael K. O'Connor, Sandra J. Gendler, and John C. Morris

1490 B-Cell Lymphomas Differ in their Responsiveness to CpG Oligodeoxynucleotides. Bernd Jahrsdorfer, Lars Mühlenhoff, Sue E. Blackwell, Moritz Wagner, Hendrik Poeck, Evelyn Hartmann, Ralf Jox, Thomas Giese, Bertold Emmerich, Stefan Endres, George J. Weiner, and Gunther Hartmann

1500 Endocrine Effects of Tamoxifen Plus Exemestane in Postmenopausal Women with Breast Cancer. Richard R. Love, Paul R. Hutson, Thomas C. Havighurst, and James F. Cleary

1504 Phase I Pharmacokinetic, Food Effect, and Pharmacogenetic Study of Oral Irinotecan Given as Semisolid Matrix Capsules in Patients with Solid Tumors. Otto Soepenberg, Herlinde Dumez, Jaap Verweij, Floris A. de Jong, Maja J.A. de Jonge, José Thomas, Ferry A.L.M. Eskens, Ron H.N. van Schaik, Johan Selleslach, Judith ter Steeg, Patricia Lefebvre, Sylvie Assadourian, Ger-Jan Sanderink, Alex Sparreboom, and Allan T. van Oosterom

1512 Phase I Study of MetXia-P450 Gene Therapy and Oral Cyclophosphamide for Patients with Advanced Breast Cancer or Melanoma. Jeremy P. Braybrooke, Andrew Slade, Gael Deplanque, Richard Harrop, Srinivasan Madhusudan, Martin D. Forster, Rachel Gibson, Andreas Makris, Denis C. Talbot, Jan Steiner, Linda White, On Kan, Stuart Naylor, Miles W. Carroll, Sue M. Kingsman, and Adrian L. Harris

1521 T Cell–Dependent Antibody Responses against Aberrantly Expressed Cyclin B1 Protein in Patients with Cancer and Premalignant Disease. Hiroyuki Suzuki, Daniel F. Graziano, John McKolanis, and Olivera J. Finn

1527 Phase I Trial of Combretastatin A-4 Phosphate with Carboplatin. Joshua H. Bilenker, Keith T. Flaherty, Mark Rosen, Lisa Davis, Maryann Gallagher, James P. Stevenson, Weijing Sun, David Vaughn, Bruce Giantonio, Ross Zimmer, Mitchell Schnall, and Peter J. O'Dwyer

1534 Polymorphisms in *ERCC1* and Grade 3 or 4 Toxicity in Non–Small Cell Lung Cancer Patients. Rebecca Suk, Sarada Gurubhagavatula, Sohee Park, Wei Zhou, Li Su, Thomas J. Lynch, John C. Wain, Donna Neuberg, Geoffrey Liu, and David C. Christiani

1539 Promoter Hypermethylation of Mismatch Repair Gene *hMLH1* Predicts the Clinical Response of Malignant Astrocytomas to Nitrosourea. Takao Fukushima, Yoichi Katayama, Takao Watanabe, Atsuo Yoshino, Akiyoshi Ogino, Takashi Ohta, and Chiaki Komine

Cancer Therapy: Preclinical

1545 HA22 (R490A) Is a Recombinant Immunotoxin with Increased Antitumor Activity without an Increase in Animal Toxicity. SookHee Bang, Satoshi Nagata, Masanori Onda, Robert J. Kreitman, and Ira Pastan

1551 Antitumor Effects of a Monoclonal Antibody that Binds Anionic Phospholipids on the Surface of Tumor Blood Vessels in Mice. Sophia Ran, Jin He, Xianming Huang, Melina Soares, Douglas Scothorn, and Philip E. Thorpe

1563 The Insulin-Like Growth Factor-I Receptor Kinase Inhibitor, NVP-ADW742, Sensitizes Small Cell Lung Cancer Cell Lines to the Effects of Chemotherapy. G. Sakuntala Warshamana-Greene, Julie Litz, Elisabeth Buchdunger, Carlos García-Echeverría, Francesco Hofmann, and Geoffrey W. Krystal

1572 Enhanced Sensitivity to the HER1/Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib Hydrochloride in Chemotherapy-Resistant Tumor Cell Lines. Qun Dai, Yi-He Ling, Marie Lia, Yi-Yu Zou, Glenn Kroog, Kenneth K. Iwata, and Roman Perez-Soler

1579 *In vitro* Canine Distemper Virus Infection of Canine Lymphoid Cells: A Prelude to Oncolytic Therapy for Lymphoma. Steven E. Suter, May B. Chein, Veronika von Messling, Becky Yip, Roberto Cattaneo, William Vernau, Bruce R. Madewell, and Cheryl A. London

1588 Patupilone Acts as Radiosensitizing Agent in Multidrug-Resistant Cancer Cells *In vitro* and *In vivo*. Barbara Hofstetter, Van Vuong, Angela Broggini-Tenzer, Stephan Bodis, Ilja F. Ciernik, Doriano Fabbro, Markus Wartmann, Gerd Folkers, and Martin Pruschy

1597 Analyses of Recombinant Vaccinia and Fowlpox Vaccine Vectors Expressing Transgenes for Two Human Tumor Antigens and Three Human Costimulatory Molecules. Kwong Y. Tsang, Claudia Palena, Junko Yokokawa, Philip M. Arlen, James L. Gulley, Gail P. Mazzara, Linda Gritz, Alicia Gómez Yafal, Sandra Ogueta, Patricia Greenhalgh, Kelledy Manson, Dennis Panicali, and Jeffrey Schlom

1608 **Formation and Antitumor Activity of PNU-159682, A Major Metabolite of Nemorubicin in Human Liver Microsomes.** Luigi Quintieri, Cristina Geroni, Marianna Fantin, Rosangela Battaglia, Antonio Rosato, William Speed, Paola Zanovello, and Maura Floreani

1618 **Effects of Nonselective Cyclooxygenase Inhibition with Low-Dose Ibuprofen on Tumor Growth, Angiogenesis, Metastasis, and Survival in a Mouse Model of Colorectal Cancer.** Min Yao, Wei Zhou, Simren Sangha, Andrew Albert, Albert J. Chang, Thomas C. Liu, and M. Michael Wolfe

1629 **Identification of CD19 and CD20 Peptides for Induction of Antigen-Specific CTLs against B-Cell Malignancies.** Jooeun Bae, Jeffrey A. Martinson, and Hans G. Klingemann

1639 **Induction of T-Cell Apoptosis in Rats by Genetically Engineered Glioma Cells Expressing Granulocyte-Macrophage Colony-Stimulating Factor and B7.1.** Sheng-Hong Tseng, Yun Chen, Chun-Jung Chang, Kuo-Feng Tai, Swei-Ming Lin, and Lih-Hwa Hwang

1650 **MEN4901/T-0128, a New Camptothecin Derivative–Carboxymethyldextran Conjugate, Has Potent Antitumor Activities in a Panel of Human Tumor Xenografts in Nude Mice.** Fumiko Fujita, Masako Koike, Masahide Fujita, Yasuo Sakamoto, Satoshi Okuno, Takayuki Kawaguchi, Shigeru Yano, Toshiro Yano, Satoko Kiuchi, Toshihisa Fujiwara, Shinzoh Kudoh, and Masatoshi Kakushima

1658 **Photochemical Targeting of Epidermal Growth Factor Receptor: A Mechanistic Study.** Mark D. Savellano and Tayyaba Hasan

1669 **Plasma and Cerebrospinal Fluid Pharmacokinetics of Intravenous Oxaliplatin, Cisplatin, and Carboplatin in Nonhuman Primates.** Shana S. Jacobs, Elizabeth Fox, Christopher Dennie, Lindsey B. Morgan, Cynthia L. McCully, and Frank M. Balis

1675 **Green Tea Extract Modulates Actin Remodeling via Rho Activity in an *In vitro* Multistep Carcinogenic Model.** Qing-Yi Lu, Yu-Sheng Jin, Allan Pantuck, Zuo-Feng Zhang, David Heber, Arie Belldegrun, Mai Brooks, Robert Figlin, and JianYu Rao

1684 **Corrections**

i **Instructions for Authors**

The Cover

Green tea extract (GTE) induces actin stress fiber and focal adhesion complex formations. This effect was blocked by C3 exoenzyme, a specific inhibitor of Rho activity. Cells cultured directly on cover glass were fixed with 3.7% paraformaldehyde and subjected for triple labeling of F-actin/paxillin/DNA. Red, Paxillin (McAb anti-paxillin followed by Cy3-conjugated Goat Anti-Mouse IgG), green, F-actin (Bodipy-conjugated phallacidin); blue, DNA (4',6-diamidino-2-phenylindole). Image was taken at 100x object under oil immersion.